Hydrotalcite–Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections
COVID-19 has been affecting millions of individuals worldwide and, thus far, there is no accurate therapeutic strategy. This critical situation necessitates novel formulations for already existing, FDA approved, but poorly absorbable drug candidates, such as niclosamide (NIC), which is of great rele...
| Հիմնական հեղինակներ: | , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
MDPI AG
2021-05-01
|
| Շարք: | Pharmaceuticals |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.mdpi.com/1424-8247/14/5/486 |